International Journal of Clinical Pharmacology Research , 7(2), 105110
Pearson, S
speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences
Recently, Pfizer also successfully secured the ownership of GLP-1 biotechnology company Metsera after a surprise bidding conflict, adding Metseras injectable asset, MET-097i (which is in Phase 2b testing and has the potential for once-a-month dosing), to its portfolio
Hims is a poor fit if your priority is the lowest possible price buying brand Wegovy directly, or using a dedicated cash-pay compounding provider, will cost less
Chen, L., Zhao, N